|
References 1. Gulati GL, Hyun BH. Blood smear examination. Hematol Oncol Clin North Am 1994;8:631-650.
2. Moreno A, Menke D. Assessment of platelet numbers and morphology in the peripheral blood smear. Clin Lab Med 2002;22:193-213, vii. 3. Rodgers RP, Levin J. Bleeding time: a guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1990;114:1187-1188. 4. Bowie EJ, Owen CA, Jr. The bleeding time. Prog Hemost Thromb 1974;2:249-271. 5. Bell A. The Ivy bleeding time. Am J Med Technol 1958;24:264-270. 6. Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990;16:1-20. 7. Lehman CM, Blaylock RC, Alexander DP, Rodgers GM. Discontinuation of the bleeding time test without detectable adverse clinical impact. Clin Chem 2001;47:1204-1211. 8. Gewirtz AS, Miller ML, Keys TF. The clinical usefulness of the preoperative bleeding time. Arch Pathol Lab Med 1996;120:353-356. 9. Peterson P, Hayes TE, Arkin CF, et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists' and American Society of Clinical Pathologists' position article. Arch Surg 1998;133:134-139. 10. Jarvis GE. Platelet aggregation: turbidimetric measurements. Methods Mol Biol 2004;272:65-76. 11. Hardeman MR, Vreeken J. The clinical significance of in vitro platelet aggregometry. Thromb Res 1990;59:807-808. 12. Hutton RA, Ludlam CA. ACP Broadsheet 122: August 1989. Platelet function testing. J Clin Pathol 1989;42:858-864. 13. Gibson J, Uhr E, Motum P, et al. Platelet aggregometry for the diagnosis of heparin induced thrombocytopenia: thrombosis syndrome (HITTS). Pathology 1987;19:105-106. 14. Brace LD. Testing for heparin-induced thrombocytopenia by platelet aggregometry. Clin Lab Sci 1992;5:80-81 15. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001;7 Suppl 1:10-15. 16. Miller CH, Platt SJ, Daniele C, Kaczor D. Evaluation of two automated methods for measurement of the ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2002;88:56-59. 17. Ermens AA, de Wild PJ, Vader HL, van der Graaf F. Four agglutination assays evaluated for measurement of von Willebrand factor (ristocetin cofactor activity). Clin Chem 1995;41:510-514. 18. Vanhoorelbeke K, Cauwenberghs N, Vauterin S, et al. A reliable and reproducible ELISA method to measure ristocetin cofactor activity of von Willebrand factor. Thromb Haemost 2000;83:107-113. 19. Vanhoorelbeke K, Cauwenberghs N, Vandecasteele G, et al. A reliable von Willebrand factor: ristocetin cofactor enzyme-linked immunosorbent assay to differentiate between type 1 and type 2 von Willebrand disease. Semin Thromb Hemost 2002;28:161-166. 20. Riddell AF, Jenkins PV, Nitu-Whalley IC, et al. Use of the collagen-binding assay for von Willebrand factor in the analysis of type 2M von Willebrand disease: a comparison with the ristocetin cofactor assay. Br J Haematol 2002;116:187-192. 21. Murdock PJ, Woodhams BJ, Matthews KB, et al. von Willebrand factor activity detected in a monoclonal antibody-based ELISA: an alternative to the ristocetin cofactor platelet agglutination assay for diagnostic use. Thromb Haemost 1997;78:1272-1277. 22. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-178. 23. Lennon MJ, Gibbs NM, Weightman WM, et al. A comparison of Plateletworks and platelet aggregometry for the assessment of aspirin-related platelet dysfunction in cardiac surgical patients. J Cardiothorac Vasc Anesth 2004;18:136-140. 24. Ortel TL, James AH, Thames EH, et al. Assessment of primary hemostasis by PFA-100 analysis in a tertiary care center. Thromb Haemost 2000;84:93-97. 25. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202. 26. Kundu SK, Heilmann EJ, Sio R, et al. Description of an in vitro platelet function analyzer: PFA-100. Semin Thromb Hemost 1995;21 Suppl 2:106-112. 27. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163. 28. Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002;9:407-415. 29. Carcao MD, Blanchette VS, Dean JA, et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br J Haematol 1998;101:70-73. 30. Fricke W, Kouides P, Kessler C, et al. A multicenter clinical evaluation of the Clot Signature Analyzer. J Thromb Haemost 2004;2:763-768. 31. Igawa T, Kornhauser R, Cilla DD, et al. Evaluation of the Clot Signature Analyzer as a hemostasis test in healthy volunteers exposed to low doses of aspirin. Clin Appl Thromb Hemost 1999;5:117-121. 32. Li CK, Hoffmann TJ, Hsieh PY, et al. The Xylum Clot Signature Analyzer: a dynamic flow system that simulates vascular injury. Thromb Res 1998;92:S67-77. 33. Faraday N, Guallar E, Sera VA, et al. Utility of whole blood hemostatometry using the clot signature analyzer for assessment of hemostasis in cardiac surgery. Anesthesiology 2002;96:1115-1122. 34. Haddadin AS, Ayoub CM, Sevarino FB, Rinder CS. Evaluation of hemostasis by the Clot Signature Analyzer: a potentially valuable device for the anesthesiologist. J Clin Monit Comput 1999;15:125-129. 35. Brubaker DB. An in vitro bleeding time test. Am J Clin Pathol 1989;91:422-429. 36. Coiffic A, Cazes E, Janvier G, et al. Inhibition of platelet aggregation by abciximab but not by aspirin can be detected by a new point-of-care test, the hemostatus. Thromb Res 1999;95:83-91. 37. Isgro F, Rehn E, Kiessling AH, et al. Platelet function test HemoSTATUS 2: tool or toy for an optimized management of hemostasis? Perfusion 2002;17:27-31. 38. Ereth MH, Nuttall GA, Klindworth JT, et al. Does the platelet-activated clotting test (HemoSTATUS) predict blood loss and platelet dysfunction associated with cardiopulmonary bypass? Anesth Analg 1997;85:259-264. 39. Ereth MH, NuttallGA, Santrach PJ, et al. The relation between the platelet-activated clotting test (HemoSTATUS) and blood loss after cardiopulmonary bypass. Anesthesiology 1998;88:962-969. 40. Wheeler GL, Braden GA, Steinhubl SR, et al. The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am Heart J 2002;143:602-611. 41. Wang JC, Aucoin-Barry D, Manuelian D, et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am J Cardiol 2003;92:1492-1494. 42. Bowbrick VA, Mikhailidis DP, Stansby G. Value of thromboelastography in the assessment of platelet function. Clin Appl Thromb Hemost 2003;9:137-142. 43. Cammerer U, Dietrich W, Rampf T, et al. The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003;96:51-57, table of contents. 44. Hendriks HG, Meijer K, de Wolf JT, et al. Effects of recombinant activated factor VII on coagulation measured by thromboelastography in liver transplantation. Blood Coagul Fibrinolysis 2002;13:309-313. 45. Huang GS, Chang JH, Lee MS, et al. The effect of anesthetic techniques on hemostatic function in arthroscopic surgery: evaluation by thromboelastography. Acta Anaesthesiol Sin 2002;40:121-126. 46. Samama CM. Thromboelastography: the next step. Anesth Analg 2001;92:563-564. 47. Ti LK, Cheong KF, Chen FG. Prediction of excessive bleeding after coronary artery bypass graft surgery: the influence of timing and heparinase on thromboelastography. J Cardiothorac Vasc Anesth 2002;16:545-550. 48. Carr ME, Jr. Measurement of platelet force: the Hemodyne hemostasis analyzer. Clin Lab Manage Rev 1995;9:312-314, 316-318, 320. 49. Carr ME, Jr. In vitro assessment of platelet function. Transfus Med Rev 1997;11:106-115. 50. Harker LA, Malpass TW, Branson HE, et al. Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release. Blood 1980;56:824-834. 51. Carr ME, Jr., Carr SL, Tildon T, et al. Batroxobin-induced clots exhibit delayed and reduced platelet contractile force in some patients with clotting factor deficiencies. J Thromb Haemost 2003;1:243-249. 52. Greilich PE, Carr ME, Zekert SL, Dent RM. Quantitative assessment of platelet function and clot structure in patients with severe coronary artery disease. Am J Med Sci 1994;307:15-20. 53. Krishnaswami A, Carr ME, Jr., Jesse RL, et al. Patients with coronary artery disease who present with chest pain have significantly elevated platelet contractile force and clot elastic modulus. Thromb Haemost 2002;88:739-744. 54. Carr ME, Jr., Hackney MH, Hines SJ, et al. Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans: two case reports. Vasc Endovascular Surg 2002;36:473-480. 55. Carr ME, Jr., Carr SL, Greilich PE. Heparin ablates force development during platelet mediated clot retraction. Thromb Haemost 1996;75:674-678. 56. Carr ME, Jr., Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res 1994;75:617-630. 57. Carr ME, Monge-Meberg P, McCardell K, Carr SL. Dermatan sulfate suppresses platelet force as it prolongs the APTT. Blood 1996;88:79b. 58. Carr ME, Zekert S. Effect of non-heparin thrombin antagonists on platelet force development during clot retraction. Thromb Haemost. 1993;69:1241. 59. Reverter JC, Beguin S, Kessels H, et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis." J Clin Invest 1996;98:863-874. 60. Investigators E. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-961. 61. Liszka-Hackzell JJ, Ekback G. Analysis of the information content in Sonoclot data and reconstruction of coagulation test variables. J Med Syst 2002;26:1-8. 62. Furuhashi M, Ura N, Hasegawa K, et al. Sonoclot coagulation analysis: new bedside monitoring for determination of the appropriate heparin dose during haemodialysis. Nephrol Dial Transplant 2002;17:1457-1462. 63. Shibata T, Sasaki Y, Hattori K, et al. Sonoclot analysis in cardiac surgery in dialysis-dependent patients. Ann Thorac Surg 2004;77:220-225. 64. Miyashita T, Kuro M. Evaluation of platelet function by Sonoclot analysis compared with other hemostatic variables in cardiac surgery. Anesth Analg 1998;87:1228-1233. 65. LaForce WR, Brudno DS, Kanto WP, Karp WB. Evaluation of the SonoClot Analyzer for the measurement of platelet function in whole blood. Ann Clin Lab Sci 1992;22:30-33. 66. Francis JL, Francis DA, Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot Analyzer and thromboelastography. Thromb Res 1994;74:335-346. 67. Simko RJ, Tsung FF, Stanek EJ. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother 1995;29:1015-1021; quiz 1061. 68. Pesola DA, Pesola HR, Pesola GR. Advantages for the use of the activated clotting time (ACT). Am J Crit Care 1995;4:414-415. 69. De Waele JJ, Van Cauwenberghe S, Hoste E, et al. The use of the activated clotting time for monitoring heparin therapy in critically ill patients. Intensive Care Med 2003;29:325-328. 70. Despotis GJ, Joist JH, Hogue CW, Jr., et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg 1995;110:46-54. 71. Jackson CM, Esnouf MP, Lindahl TL. A critical evaluation of the prothrombin time for monitoring oral anticoagulant therapy. Pathophysiol Haemost Thromb 2003;33:43-51. 72. Kitchen S, Preston FE. Standardization of prothrombin time for laboratory control of oral anticoagulant therapy. Semin Thromb Hemost 1999;25:17-25. 73. Riley RS, Rowe D, Fisher LM. Clinical utiliation of the international normalized ratio (INR). J Clin Lab Anal 2000;14:101-114. 74. Choi TS, Greilich PE, Shi C, et al. Point-of-care testing for prothrombin time, but not activated partial thromboplastin time, correlates with laboratory methods in patients receiving aprotinin or epsilon-aminocaproic acid while undergoing cardiac surgery. Am J Clin Pathol 2002;117:74-78. 75. Searles B, Nasrallah F, Graham S, Lajara RB. Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample. J Extra Corpor Technol 2002;34:178-181. 76. Shiach CR, Campbell B, Poller L, et al. Reliability of point-of-care prothrombin time testing in a community clinic: a randomized crossover comparison with hospital laboratory testing. Br J Haematol 2002;119:370-375. 77. Tripodi A, Bressi C, Carpenedo M, et al. Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. Thromb Res 2004;113:35-40. 78. Tseng LW, Hughes D, Giger U. Evaluation of a point-of-care coagulation analyzer for measurement of prothrombin time, activated partial thromboplastin time, and activated clotting time in dogs. Am J Vet Res 2001;62:1455-1460. 79. Yuoh C, Tarek Elghetany M, Petersen JR, et al. Accuracy and precision of point-of-care testing for glucose and prothrombin time at the critical care units. Clin Chim Acta 2001;307:119-123. 80. Poller L, Keown M, Chauhan N, et al. European Concerted Action on Anticoagulation (ECAA): multicentre international sensitivity index calibration of two types of point-of-care prothrombin time monitor systems. Br J Haematol 2002;116:844-850. 81. Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost 1999;25:407-418. 82. White GC, 2nd. The partial thromboplastin time: defining an era in coagulation. J Thromb Haemost 2003;1:2267-2270. 83. Olson JD. Addressing clinical etiologies of a prolonged aPTT. CAP Today 1999;13:28, 30, 32 passim. 84. Chen CC, You JY, Ho CH. The aPTT assay as a monitor of heparin anticoagulation efficacy in clinical settings. Adv Ther 2003;20:231-236. 85. Gibbar-Clements T, Shirrell D, Free G. PT and APTT: seeing beyond the numbers. Nursing 1997;27:49-51. 86. McConnell EA. APTT and PT: the tests of time. Nursing 1986;16:47. 87. Brandt JT, Arkin CF, Bovill EG, et al. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program. Arch Pathol Lab Med 1990;114:135-141. 88. Teruya J, Oropeza M, Ramsey G. A normal aPTT does not guarantee adequate coagulation factor levels. Anesthesiology 2001;94:542; author reply 543. 89. Wojtkowski TA, Rutledge JC, Matthews DC. The clinical impact of increased sensitivity PT and APTT coagulation assays. Am J Clin Pathol 1999;112:225-232. 90. Brigden ML, Johnston M. A survey of aPTT reporting in Canadian medical laboratories. The need for increased standardization. Thrombosis Interest Group of Canada. Am J Clin Pathol 2000;114:276-282. 91. Kitchen S, Jennings I, Woods TA, Preston FE. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol 1996;49:10-14. 92. Manzato F, Mengoni A, Grilenzoni A, Lippi G. Evaluation of the activated partial thromboplastin time (APTT) sensitivity to heparin using five commercial reagents: implications for therapeutic monitoring. Clin Chem Lab Med 1998;36:975-980. 93. Riley RS, Friedline J, Rogers JS, 2nd. Antiphospholipid antibodies: standardization and testing. Clin Lab Med 1997;17:395-430. 94. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun 2000;15:173-178. 95. Dahlback B. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis. Thromb Haemost 1995;74:139-148. 96. Dahlback B. Thrombophilia: the discovery of activated protein C resistance. Adv Genet 1995;33:135-175.
97. Press RD, Bauer KA, Kujovich JL, Heit JA. Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002;126:1304-1318. 98. Sahud MA. Factor VIII inhibitors. Laboratory diagnosis of inhibitors. Semin Thromb Hemost 2000;26:195-203. 99. Austen DE, Lechner K, Rizza CR, Rhymes IL. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 1982;47:72-75. 100. Verbruggen B, Novakova I, Wessels H, et al. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995;73:247-251. 101. Klinge J, Auerswald G, Budde U, et al. Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay. Haemophilia 2001;7:26-32. 102. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur J Clin Pharmacol. 2002;57:751-758 103. Hafner G, Roser M, Nauck M. Methods for the monitoring of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28:425-430 104. Nowak G. Clinical monitoring of hirudin and direct thrombin inhibitors. Semin Thromb Hemost. 2001;27:537-541 105. Fenyvesi T, Jorg I, Harenberg J. Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost. 2002;28:361-368 106. Gosselin RC, King JH, Janatpour KA, Dager WE, Larkin EC, Owings JT. Comparing Direct hrombin Inhibitors Using aPTT, Ecarin Clotting Times, and Thrombin Inhibitor Management Testing (September). Ann Pharmacother. 2004 107. Jespersen J, Sidelmann J. A study of the conditions and accuracy of the thrombin time assay of plasma fibrinogen. Acta Haematol. 1982;67:2-7 108. Aiyappa PA. Chromogenic substrate spectrophotometric assays for the measurement of clotting function. Ann N Y Acad Sci. 1981;370:812-821 109. Hutton RA. Chromogenic substrates in haemostasis. Blood Rev. 1987;1:201-206 110. Retzios AD, Rosenfeld R, Schiffman S. Enzymes of the contact phase of blood coagulation: kinetics with various chromogenic substrates and a two-substrate assay for the joint estimation of plasma prekallikrein and factor XI. J Lab Clin Med. 1988;112:560-566 111. Christensen U. Requirements for valid assays of clotting enzymes using chromogenic substrates. Thromb Haemost. 1980;43:169-174 112. Madaras F, Chew MY, Parkin JD. Automated estimation of factor Xa using the chromogenic substrate S-2222. Haemostasis. 1981;10:271-275 113. Kasahara Y. Agglutination immunoassays. In: Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. Washington, D.C.: ASM Press; 1997:7-12 114. Singer JM, Plotz CM. The latex fixation test. I. Application to the serological diagnosis of rheumatoid arthritis. Amer. J. Med. 1956;21:888-891 115. van Lente F. Light-scattering immunoassays. In: Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology (ed Fifth). Washington, D.C.: ASM Press; 1997:13-19 116. Whicher JT, Price CP, Spencer K. Immunonephelometric and immunoturbidimetric assays for proteins. Crit Rev Clin Lab Sci. 1983;18:213-260 117. Lugovskoy EV, Gritsenko PG, Kolesnikova IN, Zolotarova EN, Chernishov VI, Nieuwenhuizen W, Komisarenko SV. Two monoclonal antibodies to D-dimer-specific inhibitors of fibrin polymerization. Thromb Res. 2004;113:251-259. 118. Bounameaux H. Review: ELISA D-dimer is sensitive but not specific in diagnosing pulmonary embolism in an ambulatory clinical setting. ACP J Club. 2003;138:24. 119. Heim SW, Schectman JM, Siadaty MS, Philbrick JT. D-dimer testing for deep venous thrombosis: a metaanalysis. Clin Chem. 2004;50:1136-1147. 120. Mavromatis BH, Kessler CM. D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol. 2001;54:664-668. 121. Sadosty AT, Goyal DG, Boie ET, Chiu CK. Emergency department D-dimer testing. J Emerg Med. 2001;21:423-429. 122. Wakai A, Gleeson A, Winter D. Role of fibrin D-dimer testing in emergency medicine. Emerg Med J. 2003;20:319-325. 123. Adcock D, Joiner-Maier D. An automated, rapid ELISA for the determination of D-dimer in the evaluation of venous thrombosis. Am Clin Lab. 1999;18:6. 124. Fr V, Hainaut P, Fr T, Elamly A, Dessomme B, Lavenne E, Reynaert MS. ELISA D-dimer measurement for the clinical suspicion of pulmonary embolism in the emergency department: one-year observational study of the safety profile and physician's prescription. Acta Clin Belg. 2003;58:233-240. 125. Michiels JJ, Schroyens W, De Backer W, van der Planken M, Hoogsteden H, Pattynama PM. Non-invasive exclusion and diagnosis of pulmonary embolism by sequential use of the rapid ELISA D-dimer assay, clinical score and spiral CT. Int Angiol 2003;22:1-14.
126. Ellis DR, Eaton AS, Plank MC, Butman BT, Ebert RF. A comparative evaluation of ELISAs for D-dimer and related fibrin(ogen) degradation products. Blood Coagul Fibrinolysis 1993;4:537-549. 127. Normansell DE. Quantitation of serum immunoglobulins. Crit Rev Clin Lab Sci 1982;17:103-170. 128. Carpenter AB. Enzyme-linked Immunoassays. In: Rose NR, de Macario EC, Folds JD, Lane HC, Nakamura RM, eds. Manual of Clinical Laboratory Immunology. Washington, D.C.: ASM Press; 1997:20-29. 129. Bock JL. The new era of automated immunoassay. Am J Clin Pathol. 2000;113:628-646. 130. Gosling JP. A decade of development in immunoassay methodology. Clin. Chem. 1990;36:1408-1427. 131. Johannsson A, Ellis DH, Bates DL, Plumb AM, Stanley CJ. Enzyme amplification for immunoassays. Detection limit of one hundredth of an attomole. J. Immunol. Methods. 1986;87:7-11. 132. Ishikawa E, Hashida S, Tanaka K, Kohno T. Development and applications of ultrasensitive enzyme immunoassays for antigens and antibodies. Clin Chim Acta. 1989;185:223-230. 133. Scheffold A, Kern F. Recent developments in flow cytometry. J Clin Immunol 2000;20:400-407. 134. Stewart CC. Multiparameter flow cytometry. J Immunoassay 2000;21:255-272. 135. Bakke AC. The principles of flow cytometry. Lab Med 2001;32:207-211. 136. Givan AL. Principles of flow cytometry: an overview. Methods Cell Biol 2001;63:19-50. 137. McCoy P. Flow cytometry. In: McClatchey KD, ed. Clinical Laboratory Medicine (ed 2nd). Philadelphia: Lippincott, Williams, and Wilkins; 2002:1401-1425. 138. Chapman GV. Instrumentation for flow cytometry. J Immunol Methods 2000;243:3-12. 139. Bode AP, Hickerson DHM. Flow cytometry of platelets for clinical analysis. Hematol Oncol Clin North Amer 2002;In Press. 140. George JN. Platelet immunoglobulin G: its significance for the evaluation of thrombocytopenia and for understanding the origin of alpha-granule proteins. Blood 1990;76:859-870. 141. Deckmyn H, Ulrichts H, Van De Walle G, Vanhoorelbeke K. Platelet antigens and their function. Vox Sang 2004;87 Suppl 2:105-111. 142. Metcalfe P, Watkins NA, Ouwehand WH, et al. Nomenclature of human platelet antigens. Vox Sang 2003;85:240-245. 143. Rozman P. Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation. Transpl Immunol 2002;10:165-181. 144. Marti GE, Magruder L, Schuette WE, Gralnick HR. Flow cytometric analysis of platelet surface antigens. Cytometry 1988;9:448-455. 145. Neumller J, Tohidast-Akrad M, Jilch R, et al. Standardization of the flow cytometric determination of HLA class I antigens, 'platelet-specific' glycoproteins and activation markers. Vox Sang 1995;68:109-120. 146. Loudova M, Vokurkova D, Hoskova J, Krejsek J. Immunofluorescence determinatin using flow cytometry of platelet surface antigens in peripheral blood of healthy individuals (pilot study). Vnitr Lek 2002;48:632-637. 147. Ault KA, Rinder HM, Mitchell J, et al. The significance of platelets with increased RNA content (reticulated platelets). A measure of the rate of thrombopoiesis. Am J Clin Pathol 1992;98:637-646. 148. Takubo T, Yamane T, Hino M, et al. Clinical significance of simultaneous measurement of reticulated platelets and large platelets in idiopathic thrombocytopenic purpura. Haematologia (Budap). 2000;30:183-192. 149. Takubo T, Yamane T, Hino M, et al. Usefulness of determining reticulated and large platelets in idiopathic thrombocytopenic purpura. Acta Haematol 1998;99:109-110. 150. Kurata Y, Hayashi S, Kiyoi T, et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001;115:656-664. 151. Joutsi-Korhonen L, Sainio S, Riikonen S, et al. Detection of reticulated platelets: estimating the degree of fluorescence of platelets stained with thiazole orange. Eur J Haematol 2000;65:66-71. 152. Russell KE, Perkins PC, Grindem CB, et al. Flow cytometric method for detecting thiazole orange-positive (reticulated) platelets in thrombocytopenic horses. Am J Vet Res 1997;58:1092-1096. 153. Tsao PW, Bozarth JM, Jackson SA, et al. Platelet GPIIb/IIIa receptor occupancy studies using a novel fluoresceinated cyclic Arg-Gly-Asp peptide. Thromb Res 1995;77:543-556. 154. Ryu T. Multimer analysis of von Willebrand factor using monoclonal antibody. Nippon Ketsueki Gakkai Zasshi 1987;50:1689-1696 155. Tomita Y, Harrison J, Abildgaard CF. von Willebrand factor multimer analysis using a sensitive peroxidase staining method. Thromb Haemost 1989;62:781-783. 156. Spronk HM, Govers-Riemslag JW, ten Cate H. The blood coagulation system as a molecular machine. Bioessays 2003;25:1220-1228. 157. Oldenburg J, Schwaab R. Molecular biology of blood coagulation. Semin Thromb Hemost 2001;27:313-324. 158. Antonarakis SE. Molecular genetics of coagulation factor VIII gene and haemophilia A. Haemophilia 1998;4 Suppl 2:1-11. 159. Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 1997;8:118-125. 160. Crowther MA, Kelton JG. Congenital thrombophilic states associated with venous thrombosis: a qualitative overview and proposed classification system. Ann Intern Med 2003;138:128-134. 161. Dahlback B. The discovery of activated protein C resistance. J Thromb Haemost 2003;1:3-9. 162. Nicolaes GA, Dahlback B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003;17:37-61, vi. 163. Van Cott EM, Soderberg BL, Laposata M. Activated protein C resistance, the factor V Leiden mutation, and a laboratory testing algorithm. Arch Pathol Lab Med 2002;126:577-582. 164. Leroyer C, Mercier B, Oger E, Chenu E, Abgrall JF, Ferec C, Mottier D. Prevalence of 20210 A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost 1998;80:49-51. 165. Vicente V, Gonzalez-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica 1999;84:356-362. 166. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999;82:1395-1398. 167. Bick RL. Prothrombin G20210A mutation, antithrombin, heparin cofactor II, protein C, and protein S defects. Hematol Oncol Clin North Am 2003;17:9-36. 168. McGlennen RC, Key NS. Clinical and laboratory management of the prothrombin G20210A mutation. Arch Pathol Lab Med 2002;126:1319-1325. 169. Eichinger S, Stumpflen A, Hirschl M, et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998;80:566-569. 170. Keijzer MB, den Heijer M, Blom HJ, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolatereductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002;88:723-728.
171. Nagy PL, Schrijver I, Zehnder JL. Molecular diagnosis of hypercoagulable states. Lab Med 2004;35:214-221. 172. White JG. Electron microscopy methods for studying platelet structure and function. Methods Mol Biol 2004;272:47-64. 173. White JG. Use of the electron microscope for diagnosis of platelet disorders. Semin Thromb Hemost 1998;24:163-168. 174. White JG. Morphological studies of platelets and platelet reactions. Vox Sang 1981;40 Suppl 1:8-17. 175. White JG, Gerrard JM. The ultrastructure of defective human platelets. Mol Cell Biochem 1978;21:109-128. 176. White JG. The dense bodies of human platelets: inherent electron opacity of the serotonin storage particles. Blood 1969;33:598-606
|